Biohaven Ltd BHVN

NYS: BHVN | ISIN: VGG111961055 30/04/2025

22,12 USD (+1,10%)

(+1,10%) 30/04/2025

Grafiek Biohaven Ltd

Grafiek Biohaven Ltd

1 dag1d 1,10%
1 week1w -5,47%
1 maand1m -2,12%
3 maanden3m -41,34%
6 maanden6m -56,53%
1 jaar1j -44,95%
5 jaar5j -50,92%

Biohaven Ltd in het nieuws

Toon enkel gratis nieuws

28 april 2025 · Biohaven Announces Investment up to $600 Million by Oberland Capital · Persbericht

5 april 2025 · Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting · Persbericht

3 maart 2025 · Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 · Persbericht

3 maart 2025 · Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results · Persbericht

8 augustus 2024 · Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments · Persbericht

29 mei 2024 · Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day · Persbericht

29 mei 2024 · Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors · Persbericht

9 mei 2024 · Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments · Persbericht

22 april 2024 · Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares · Persbericht

18 april 2024 · Biohaven Announces Pricing of $230 Million Public Offering of Common Shares · Persbericht

Profiel Biohaven Ltd

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: biohavenpharma.com

Hoofdzetel: New Haven, Connecticut Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe